ReviewNature reviews. Drug discovery2012
The potential of biologics for the treatment of asthma.
Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma
Observatory of Patients With Severe Asthma and Potential Eligible Patients for Treatment With Biological Drugs
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 225 citations in OpenAlex.
- Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized Controlled Trials.Current allergy and asthma reports · 2021Pooled it
- Asthma and the risk of lung cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.The Journal of allergy and clinical immunology · 2023Trial
- Trial
- Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.Drugs · 2026Review
- Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review.Current allergy and asthma reports · 2025Article
- Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach.Journal of clinical medicine · 2025Review
- Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma.Nature communications · 2025Article
- Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Insights into sepsis-induced apoptosis: Interplay between programmed cell death and interleukin-7.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2025Review
- Gingival-derived mesenchymal stem cells alleviate allergic asthma inflammation via HGF in animal models.iScience · 2024Article
- Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts.Respiratory research · 2023Article
- The Road Toward Transformative Treatments for Food Allergy.Frontiers in allergy · 2022Review
- miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma.Frontiers in immunology · 2022Article
- RhoA and Cdc42 in T cells: Are they targetable for T cell-mediated inflammatory diseases?Precision clinical medicine · 2021Article
- Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators.Inflammopharmacology · 2021Review
- An endothelial microRNA-1-regulated network controls eosinophil trafficking in asthma and chronic rhinosinusitis.The Journal of allergy and clinical immunology · 2020Article
- Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide.The Journal of international medical research · 2020Article
- G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.Pharmacological reviews · 2020Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in the knowledge of asthma pathobiology suggest that biological therapies that target cytokines can be potentially useful for the treatment of this complex and heterogeneous airway disease. The use of biologics in asthma has been established with the approval of the humanized monoclonal immunoglobulin E-targeted antibody omalizumab (Xolair; Genentech/Novartis) as an add-on treatment for inadequately controlled disease. Furthermore, evidence is accumulating in support of the efficacy of other biologics, such as interleukin-5 (IL-5)- and IL-13-specific drugs. Therefore, these new developments are changing the scenario of asthma therapies, especially with regard to more severe disease. The variability among patients' individual therapeutic responses highlights that it will be necessary to characterize the different asthma subtypes so that phenotype-targeted treatments based on the use of biologics can be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.